.jpg)
PROTEIN TYROSINE PHOSPHATASES AS BIOMARKERS FOR HEPATOCELLULAR CARCINOMA AND USES THEREOF
PCT/EP2022/058188
This application discloses in vitro methods for the diagnosis, prognosis, and/or monitoring of cancer, in particular liver cancer or hepatocellular carcinoma (HCC) based on the aggregate expression level and oxidation level of all protein tyrosine phosphatases in a sample; whether or not in combination with the differential expression of protein tyrosine phosphatases individually. Also provided are in vitro methods for the selection of a prophylactic or therapeutic treatment or the evaluate the efficacy of a therapeutic treatment. Further, the present application provides a kit to be used in said methods.
Key advantages of the technology Proteomic assay enabling diagnosis and patient stratification of according to stage of transition from steatosis/NAFLD/NASH to HCC from human biopsies. Robust Mass-Spectrometry method enabling direct analysis of biopsy samples also conducive to the development of blood-based biomarker assays, including ELISA. Potential applications Proteomic assay enabling NAFLD/NASH/HCC diagnosis, prognosis and patient stratification for therapeutic treatment decision-making Companion diagnostic for assessing treatment efficacy including innovative approaches under clinical development Possible implementation as blood-based assay suitable for clinical settings
Pending PCT patent application to be published on Sept 29th 2022 (ahead of the P4I fair). The patent link shall be updated upon publication in the corresponding Licensing Opportunity Brief (for which the link is provided).